{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:30:02Z","timestamp":1787689802759,"version":"build-2784847793"},"reference-count":200,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Sodium\u2013glucose cotransporter-2 (SGLT2) inhibitors, initially developed as antidiabetic agents, have recently gained attention for their potential role in modulating processes relevant to Alzheimer\u2019s disease (AD). Preclinical studies suggest that they may influence key mechanisms involved in AD. However, available clinical studies, mainly retrospective and focused on diabetic populations, provide insufficient clarity on whether these effects extend to broader, non-diabetic groups. The heterogeneity of neurodegenerative diseases, which differ in inflammatory and proteotoxic mechanisms, further highlights the need for disease-specific investigations. This review examines mechanistic pathways through which SGLT2 inhibition may influence AD progression and evaluates current clinical evidence, aiming to identify key knowledge gaps and guide future research. This review summarises the latest evidence from the literature, focusing on preclinical experiments, translational studies and early clinical observations. The search focused on pathways related to microglial and astrocytic activation, oxidative stress, metabolic remodeling, neuronal survival, and amyloid and tau dynamics. Accumulating data indicate that SGLT2 inhibitors exert multifaceted actions relevant to AD pathology, including reduced neuroinflammation and oxidative stress, improved mitochondrial and insulin signaling, as well as decreased amyloid deposition and tau hyperphosphorylation. Additionally, SGLT2 inhibition may improve cerebrovascular perfusion and blood\u2013brain barrier stability, potentially supporting cognitive function. Nonetheless, major challenges remain, including variable blood\u2013brain barrier permeability and heterogeneous experimental responses. SGLT2 inhibitors represent a promising pleiotropic class of compounds with potential disease-modifying effects in AD. Their capacity to target metabolic, inflammatory, and proteotoxic pathways makes them attractive candidates for neurodegenerative therapy. Further studies are required to clarify biochemical pathways and validate clinical efficacy.<\/jats:p>","DOI":"10.3390\/ijms27115051","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:46:48Z","timestamp":1780494408000},"page":"5051","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SGLT2 Inhibitors in Alzheimer\u2019s Disease: Biochemical Insights and Therapeutic Potential"],"prefix":"10.3390","volume":"27","author":[{"given":"Pietro","family":"Mazzeo","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy"},{"name":"Division of Cardiology, Cardiovascular Department, Azienda Ospedaliera Regionale \u201cSan Carlo\u201d, 85100 Potenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6471-5246","authenticated-orcid":false,"given":"Mariapia","family":"Vietri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0509-3886","authenticated-orcid":false,"given":"Nicola","family":"Tecce","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical Medicine and Surgery, Federico II University, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Delizia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Remondelli","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6592-4373","authenticated-orcid":false,"given":"Tania","family":"Ciaglia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Di Dio","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Corletti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine Gerardo","family":"Pizzuti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Pepe","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy"},{"name":"National Biodiversity Future Center (NBFC), 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Stabile","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Department, Azienda Ospedaliera Regionale \u201cSan Carlo\u201d, 85100 Potenza, Italy"},{"name":"Department of Health Sciences, University of Basilicata, 85100 Potenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7863-253X","authenticated-orcid":false,"given":"Michele","family":"Correale","sequence":"additional","affiliation":[{"name":"Emergency and Urgency Department, Ospedali Riuniti University Hospital, 71100 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-2181","authenticated-orcid":false,"given":"Pietro","family":"Campiglia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8296-1888","authenticated-orcid":false,"given":"Maria Rosaria","family":"Miranda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy"},{"name":"Department of Medicine, Digestive Health Research Institute, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2355-6047","authenticated-orcid":false,"given":"Mario Felice","family":"Tecce","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-5526","authenticated-orcid":false,"given":"Vincenzo","family":"Vestuto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Salerno, Via G. Paolo II, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-12-804766-8.00009-1","article-title":"Epidemiology of Aging and Associated Cognitive Disorders: Prevalence and Incidence of Alzheimer\u2019s Disease and Other Dementias","volume":"167","author":"Lopez","year":"2019","journal-title":"Handb. Clin. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Pagano, K., Tomaselli, S., Molinari, H., and Ragona, L. (2020). Natural Compounds as Inhibitors of A\u03b2 Peptide Aggregation: Chemical Requirements and Molecular Mechanisms. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.619667"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chapple, B., Bayliss, E., Woodfin, S., Smith, M., Winter, J., and Moore, W. (2025). Type 3 Diabetes: Linking Insulin Resistance to Cognitive Decline. Diseases, 13.","DOI":"10.3390\/diseases13110359"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/193229680800200619","article-title":"Alzheimer\u2019s Disease Is Type 3 Diabetes\u2014Evidence Reviewed","volume":"2","author":"Wands","year":"2008","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13543784.2022.2022122","article-title":"New Treatment Approaches for Alzheimer\u2019s Disease: Preclinical Studies and Clinical Trials Centered on Antidiabetic Drugs","volume":"31","author":"Katsenos","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Michailidis, M., Tata, D.A., Moraitou, D., Kavvadas, D., Karachrysafi, S., Papamitsou, T., Vareltzis, P., and Papaliagkas, V. (2022). Antidiabetic Drugs in the Treatment of Alzheimer\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094641"},{"key":"ref_7","first-page":"1251","article-title":"Effect of Dapagliflozin Combined with Cognitive Behavior Training on Quality of Life and Cognitive Function in Elderly Patients with Type 2 Diabetes Mellitus Complicated with Mild Cognitive Impairment","volume":"51","author":"Zhao","year":"2022","journal-title":"Iran. J. Public Health"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Pawlos, A., Broncel, M., Wo\u017aniak, E., and Gorzelak-Pabi\u015b, P. (2021). Neuroprotective Effect of SGLT2Inhibitors. Molecules, 26.","DOI":"10.3390\/molecules26237213"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"114134","DOI":"10.1016\/j.physbeh.2023.114134","article-title":"The Sodium Glucose Co-Transporter 2 Inhibitor Ertugliflozin for Alzheimer\u2019s Disease: Inhibition of Brain Insulin Signaling Disruption-Induced Tau Hyperphosphorylation","volume":"263","author":"Pang","year":"2023","journal-title":"Physiol. Behav."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s12272-020-01237-y","article-title":"Empagliflozin Alleviates Neuronal Apoptosis Induced by Cerebral Ischemia\/Reperfusion Injury through HIF-1\u03b1\/VEGF Signaling Pathway","volume":"43","author":"Rifaai","year":"2020","journal-title":"Arch. Pharmacal Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11011-024-01478-6","article-title":"The SGLT2 Inhibitor Empagliflozin Exerts Neuroprotective Effect against Hydrogen Peroxide-Induced Toxicity on Primary Neurons","volume":"40","author":"Davri","year":"2024","journal-title":"Metab. Brain Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Fonseca-Correa, J.I., and Correa-Rotter, R. (2021). Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front. Med., 8.","DOI":"10.3389\/fmed.2021.777861"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Katsimardou, A., Theofilis, P., Vordoni, A., Doumas, M., and Kalaitzidis, R.G. (2024). The Effects of SGLT2 Inhibitors on Blood Pressure and Other Cardiometabolic Risk Factors. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212384"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.2174\/1568026619666190828161409","article-title":"Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction","volume":"19","author":"Liu","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal Effects of SGLT2 Inhibitors: An Update","volume":"29","author":"Nespoux","year":"2020","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control over 2 Weeks in Patients with Type 2 Diabetes Mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients with Type 1 Diabetes Mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","article-title":"Sodium Glucose Cotransport-2 Inhibition and Intrarenal RAS Activity in People with Type 1 Diabetes","volume":"86","author":"Cherney","year":"2014","journal-title":"Kidney Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin, a Glucose-Regulating Drug with Diuretic Properties in Subjects with Type 2 Diabetes","volume":"15","author":"Wie","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int."},{"key":"ref_25","unstructured":"Padda, I.S., Mahtani, A.U., and Parmar, M. (2025). Sodium-Glucose Transport 2 (SGLT2) Inhibitors, StatPearls."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.neubiorev.2016.03.005","article-title":"Diabetes and Alzheimer\u2019s Disease Crosstalk","volume":"64","author":"Shi","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Md Roslan, A.H., Tengku Muhazan Shah, T.M.H., Mohd Saffian, S., John, L.J., Che Ramli, M.D., Nassir, C.M.N.C.M., Mahadi, M.K., and Hein, Z.M. (2026). Neuroprotective Potential of SGLT2 Inhibitors in Animal Models of Alzheimer\u2019s Disease and Type 2 Diabetes Mellitus: A Systematic Review. Pharmaceuticals, 19.","DOI":"10.3390\/ph19010166"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, Design, and Baseline Characteristics of the CANVAS Study","volume":"166","author":"Neal","year":"2013","journal-title":"Am. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin Reduced Mortality and Hospitalization for Heart Failure","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.14797\/mdcvj.1120","article-title":"SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review","volume":"18","author":"Kansara","year":"2022","journal-title":"Methodist Debakey Cardiovasc. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: DELIVER Trial Design","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/s12933-024-02515-5","article-title":"The Effects of Dapagliflozin in a Real-World Population of HFrEF Patients with Different Hemodynamic Profiles","volume":"23","author":"Loria","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s10557-021-07254-3","article-title":"Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure","volume":"36","author":"Correale","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e70101","DOI":"10.1111\/acel.70101","article-title":"SGLT2 Inhibition by Enavogliflozin Significantly Reduces A\u03b2 Pathology and Restores Cognitive Function via Upregulation of Microglial AMPK Signaling in 5XFAD Mouse Model of Alzheimer\u2019s Disease","volume":"24","author":"Han","year":"2025","journal-title":"Aging Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/neurolint16060124","article-title":"New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia","volume":"16","author":"Hung","year":"2024","journal-title":"Neurol. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.hfc.2022.03.002","article-title":"SGLT2 Inhibitors and Safety in Older Patients","volume":"18","author":"Pollack","year":"2022","journal-title":"Heart Fail. Clin."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1210\/jc.2019-00198","article-title":"Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline","volume":"104","author":"LeRoith","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1007\/s12325-020-01329-7","article-title":"Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus","volume":"37","author":"Clark","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/jgs.14028","article-title":"Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis","volume":"64","author":"Sinclair","year":"2016","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study","volume":"43","author":"Cahn","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"111796","DOI":"10.1016\/j.diabres.2024.111796","article-title":"Impact of Age on eGFR Dynamics Following Sodium-Glucose Cotransporter 2 Inhibitor Therapy: A Real-World Study","volume":"214","author":"An","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12933-023-01743-5","article-title":"The Real-World Safety Profile of Sodium-Glucose Co-Transporter-2 Inhibitors among Older Adults (\u226575 Years): A Retrospective, Pharmacovigilance Study","volume":"22","author":"Goldman","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.diabet.2020.01.002","article-title":"Reduction in HbA1c with SGLT2 Inhibitors vs. DPP-4 Inhibitors as Add-Ons to Metformin Monotherapy According to Baseline HbA1c: A Systematic Review of Randomized Controlled Trials","volume":"46","author":"Scheen","year":"2020","journal-title":"Diabetes Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.ajkd.2021.02.335","article-title":"Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression","volume":"78","author":"Neuen","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lardaro, A., Quarta, L., Pagnotta, S., Sodero, G., Mariani, S., Del Ben, M., Desideri, G., Ettorre, E., and Baratta, F. (2024). Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081750"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Szablewski, L. (2025). Associations Between Diabetes Mellitus and Neurodegenerative Diseases. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020542"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Muddapu, V.R., Dharshini, S.A.P., Chakravarthy, V.S., and Gromiha, M.M. (2020). Neurodegenerative Diseases\u2014Is Metabolic Deficiency the Root Cause?. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.00213"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2174\/1570159X18666200122122512","article-title":"Role of Oxidative Stress and Metal Toxicity in the Progression of Alzheimer\u2019s Disease","volume":"18","author":"Birla","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/dmrr.2718","article-title":"Oxidative Stress, Type 2 Diabetes and Vitamin D: Past, Present and Future","volume":"32","author":"Nikooyeh","year":"2016","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/oxygen3030022","article-title":"The Ion Channels Involved in Oxidative Stress-Related Gastrointestinal Diseases","volume":"3","author":"Miranda","year":"2023","journal-title":"Oxygen"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41392-024-02095-6","article-title":"Redox Regulation: Mechanisms, Biology and Therapeutic Targets in Diseases","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Miranda, M.R., Basilicata, M.G., Vestuto, V., Aquino, G., Marino, P., Salviati, E., Ciaglia, T., Dom\u00ednguez-Rodr\u00edguez, G., Moltedo, O., and Campiglia, P. (2024). Anticancer Therapies Based on Oxidative Damage: Lycium barbarum Inhibits the Proliferation of MCF-7 Cells. Antioxidants, 13.","DOI":"10.3390\/antiox13060708"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Vietri, M., Miranda, M.R., Amodio, G., Ciaglia, T., Bertamino, A., Campiglia, P., Remondelli, P., Vestuto, V., and Moltedo, O. (2025). The Link Between Endoplasmic Reticulum Stress and Lysosomal Dysfunction under Oxidative Stress in Cancer Cells. Biomolecules, 15.","DOI":"10.3390\/biom15070930"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zarrella, S., Miranda, M.R., Covelli, V., Restivo, I., Novi, S., Pepe, G., Tesoriere, L., Rodriguez, M., Bertamino, A., and Campiglia, P. (2025). Endoplasmic Reticulum Stress and Its Role in Metabolic Reprogramming of Cancer. Metabolites, 15.","DOI":"10.3390\/metabo15040221"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Vestuto, V., Di Sarno, V., Musella, S., Di Dona, G., Moltedo, O., Gomez-Monterrey, I.M., Bertamino, A., Ostacolo, C., Campiglia, P., and Ciaglia, T. (2022). New Frontiers on ER Stress Modulation: Are TRP Channels the Leading Actors?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010185"},{"key":"ref_65","first-page":"659","article-title":"Oxidative Stress: A Unifying Paradigm in Hypertension","volume":"36","author":"Touyz","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Veselov, I.M., Vinogradova, D.V., Maltsev, A.V., Shevtsov, P.N., Spirkova, E.A., Bachurin, S.O., and Shevtsova, E.F. (2023). Mitochondria and Oxidative Stress as a Link between Alzheimer\u2019s Disease and Diabetes Mellitus. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914450"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/dmrr.2732","article-title":"Antioxidant Treatment Ameliorates Experimental Diabetes-Induced Depressive-like Behaviour","volume":"32","author":"Abelaira","year":"2016","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/13872877241307404","article-title":"Insulin Signaling and Oxidative Stress: Bridging the Gap between Type 2 Diabetes Mellitus and Alzheimer\u2019s Disease","volume":"103","author":"Xu","year":"2025","journal-title":"J. Alzheimers Dis."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Tsai, Y.R., Chang, C.F., Lai, J.H., Wu, J.C., Chen, Y.H., Kang, S.J., Hoffer, B.J., Tweedie, D., Luo, W., and Greig, N.H. (2018). Pomalidomide Ameliorates H2O2-Induced Oxidative Stress Injury. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103252"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Rickards, L., Lynn, A., Harrop, D., Barker, M.E., Russell, M., and Ranchordas, M.K. (2021). Effect of Polyphenol-Rich Foods on Recovery from Exercise-Induced Muscle Damage. Nutrients, 13.","DOI":"10.3390\/nu13092988"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Detka, J., P\u0142achtij, N., Strzelec, M., Manik, A., and Sa\u0142at, K. (2024). p38\u03b1 MAPK as an Emerging Drug Target for Alzheimer\u2019s Disease. Molecules, 29.","DOI":"10.3390\/molecules29184354"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1515\/revneuro-2018-0008","article-title":"Role of p38\/MAPKs in Alzheimer\u2019s Disease","volume":"30","author":"Kheiri","year":"2018","journal-title":"Rev. Neurosci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCRESAHA.117.310725","article-title":"Physiological Mitochondrial Fragmentation Is a Normal Cardiac Adaptation","volume":"122","author":"Coronado","year":"2018","journal-title":"Circ. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e21620","DOI":"10.1096\/fj.202100067R","article-title":"Mitochondrial fusion and fission: The fine-tune balance for cellular homeostasis","volume":"35","author":"Adebayo","year":"2021","journal-title":"FASEB J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"18021","DOI":"10.1038\/s41598-025-01820-7","article-title":"Integrated proteomics highlights functional activation induced by advanced-platelet rich fibrin plus (A-PRF+) in primary equine fibroblasts","volume":"15","author":"Miranda","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"E750","DOI":"10.1152\/ajpendo.00179.2019","article-title":"Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes","volume":"318","author":"Cheng","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cellsig.2011.05.021","article-title":"The regulation of mitochondrial morphology: Intricate mechanisms and dynamic machinery","volume":"23","author":"Palmer","year":"2011","journal-title":"Cell. Signal."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00125-009-1553-y","article-title":"Diabetes regulates mitochondrial biogenesis and fission in mouse neurons","volume":"53","author":"Edwards","year":"2010","journal-title":"Diabetologia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1126\/science.1104343","article-title":"Mitochondrial dysfunction and type 2 diabetes","volume":"307","author":"Lowell","year":"2005","journal-title":"Science"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.2337\/db14-0758","article-title":"Drp1-mediated mitochondrial abnormalities link to synaptic injury in diabetes model","volume":"64","author":"Huang","year":"2015","journal-title":"Diabetes"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/bs.pmbts.2016.12.019","article-title":"Mitochondrial perturbation in Alzheimer\u2019s disease and diabetes","volume":"146","author":"Akhter","year":"2017","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.apsb.2024.10.004","article-title":"Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications","volume":"15","author":"Dash","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7086512","DOI":"10.1155\/2021\/7086512","article-title":"Oxidative stress, neuroinflammation, and NADPH oxidase: Implications in the pathogenesis and treatment of Alzheimer\u2019s disease","volume":"2021","author":"Ganguly","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Raz, L., Zhang, Q.G., Zhou, C.F., Han, D., Gulati, P., Yang, L.C., Yang, F., Wang, R.M., and Brann, D.W. (2010). Role of Rac1 GTPase in NADPH oxidase activation and cognitive impairment following cerebral ischemia in the rat. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012606"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"114830","DOI":"10.1016\/j.bbr.2023.114830","article-title":"Empagliflozin alleviates diabetes-induced cognitive impairments by lowering nicotinamide adenine dinucleotide phosphate oxidase-4 expression and potentiating the antioxidant defense system in brain tissue of diabetic rats","volume":"460","author":"Yaribeygi","year":"2024","journal-title":"Behav. Brain Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mad.2015.04.001","article-title":"PARP-1 involvement in neurodegeneration: A focus on Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"146\u2013148","author":"Martire","year":"2015","journal-title":"Mech. Ageing Dev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s11064-012-0895-x","article-title":"Activation of PARP by oxidative stress induced by \u03b2-amyloid: Implications for Alzheimer\u2019s disease","volume":"37","author":"Abeti","year":"2012","journal-title":"Neurochem. Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Maggiore, A., Casale, A.M., Toscanelli, W., Cappucci, U., Rotili, D., Grieco, M., Gagn\u00e9, J.P., Poirier, G.G., d\u2019Erme, M., and Piacentini, L. (2022). Neuroprotective effects of PARP inhibitors in Drosophila models of Alzheimer\u2019s disease. Cells, 11.","DOI":"10.3390\/cells11081284"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.freeradbiomed.2011.01.037","article-title":"PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: Correlation with peripheral nerve function","volume":"50","author":"Lupachyk","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Mizukami, H., and Osonoi, S. (2020). Pathogenesis and molecular treatment strategies of diabetic neuropathy collateral glucose-utilizing pathways in diabetic polyneuropathy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010094"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1471-4159.2007.04880.x","article-title":"Aldose reductase is implicated in high glucose-induced oxidative stress in mouse embryonic neural stem cells","volume":"103","author":"Fu","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Huang, Y.K., Liu, C.C., Wang, S., Cheng, H.C., Meadows, C., and Chang, K.C. (2022). The role of aldose reductase in beta-amyloid-induced microglia activation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232315088"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"C981","DOI":"10.1152\/ajpcell.00191.2023","article-title":"Hexosamine biosynthetic pathway and O-GlcNAc cycling of glucose metabolism in brain function and disease","volume":"325","author":"Kim","year":"2023","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/brain\/awp099","article-title":"Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer\u2019s disease","volume":"132","author":"Liu","year":"2009","journal-title":"Brain"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/jnr.25196","article-title":"Cognitive dysfunction and increased phosphorylated tau are associated with reduced O-GlcNAc signaling in an aging mouse model of metabolic syndrome","volume":"101","author":"Gupta","year":"2023","journal-title":"J. Neurosci. Res."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Wu, H.F., Huang, C.W., Art, J., Liu, H.X., Hart, G.W., and Zeltner, N. (2023). O-GlcNAcylation is crucial for sympathetic neuron development, maintenance, functionality and contributes to peripheral neuropathy. Front. Neurosci., 17.","DOI":"10.3389\/fnins.2023.1137847"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/382685a0","article-title":"RAGE and amyloid-beta peptide neurotoxicity in Alzheimer\u2019s disease","volume":"382","author":"Yan","year":"1996","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1533317506289277","article-title":"Toxic advanced glycation end products (TAGE) theory in Alzheimer\u2019s disease","volume":"21","author":"Sato","year":"2006","journal-title":"Am. J. Alzheimer\u2019s Dis. Other Dement."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"113287","DOI":"10.1016\/j.physbeh.2020.113287","article-title":"Hyperglycemia induces RAGE-dependent hippocampal spatial memory impairments","volume":"229","author":"Momeni","year":"2021","journal-title":"Physiol. Behav."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1038\/sj.emboj.7600415","article-title":"RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice","volume":"23","author":"Arancio","year":"2004","journal-title":"EMBO J."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Li, W., Chen, Q., Peng, C., Yang, D., Liu, S., Lv, Y., Jiang, L., Xu, S., and Huang, L. (2025). Roles of the receptor for advanced glycation end products and its ligands in the pathogenesis of Alzheimer\u2019s disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26010403"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e1288","DOI":"10.1038\/cddis.2014.248","article-title":"Genetic deficiency of neuronal RAGE protects against AGE-induced synaptic injury","volume":"5","author":"Zhang","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2017.12.026","article-title":"Targeted inhibition of RAGE reduces amyloid-\u03b2 influx across the blood-brain barrier and improves cognitive deficits in db\/db mice","volume":"131","author":"Wang","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12974-025-03489-1","article-title":"Targeting the RAGE-RIPK1 binding site attenuates diabetes-associated cognitive deficits","volume":"22","author":"Gao","year":"2025","journal-title":"J. Neuroinflammation"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1210\/en.2005-1464","article-title":"Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-kinase-dependent mechanism","volume":"147","author":"Benomar","year":"2006","journal-title":"Endocrinology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bbr.2017.09.033","article-title":"Insulin modulates hippocampally-mediated spatial working memory via glucose transporter-4","volume":"338","author":"Jahagirdar","year":"2018","journal-title":"Behav. Brain Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"113076","DOI":"10.1016\/j.expneurol.2019.113076","article-title":"GluT4: A central player in hippocampal memory and brain insulin resistance","volume":"323","author":"McNay","year":"2020","journal-title":"Exp. Neurol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1523\/JNEUROSCI.1700-16.2016","article-title":"Novel roles for the insulin-regulated glucose transporter-4 in hippocampally dependent memory","volume":"36","author":"McNay","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014A novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2 -inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats","volume":"333","author":"Tanajak","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1007\/s13311-021-01140-4","article-title":"Crosstalk among NLRP3 inflammasome, ETBR signaling, and miRNAs in stress-induced depression-like behavior: A modulatory role for SGLT2 inhibitors","volume":"18","author":"Muhammad","year":"2021","journal-title":"Neurotherapeutics"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/jnc.14551","article-title":"RS1 (Rsc1A1) deficiency limits cerebral SGLT1 expression and delays brain damage after experimental traumatic brain injury","volume":"147","author":"Sebastiani","year":"2018","journal-title":"J. Neurochem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00414-018-1893-6","article-title":"Validation of sodium\/glucose cotransporter proteins in human brain as a potential marker for temporal narrowing of the trauma formation","volume":"133","author":"Oerter","year":"2019","journal-title":"Int. J. Leg. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","article-title":"Targeting ROS-dependent AKT\/GSK-3\u03b2\/NF-\u03baB and DJ-1\/Nrf2 pathways by dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson\u2019s disease rat model","volume":"12","author":"Arab","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Lin, K.J., Wang, T.J., Chen, S.D., Lin, K.L., Liou, C.W., Lan, M.Y., Chuang, Y.C., Chuang, J.H., Wang, P.W., and Lee, J.J. (2021). Two birds one stone: The neuroprotective effect of antidiabetic agents on Parkinson disease\u2014Focus on sodium-glucose cotransporter 2 (SGLT2) inhibitors. Antioxidants, 10.","DOI":"10.3390\/antiox10121935"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-020-00607-4","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer\u2019s disease and type 2 diabetes","volume":"12","author":"Herrera","year":"2020","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"109080","DOI":"10.1016\/j.intimp.2022.109080","article-title":"The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents","volume":"111","author":"Theofilis","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Heimke, M., Lenz, F., Rickert, U., Lucius, R., and Cossais, F. (2022). Anti-inflammatory properties of the SGLT2 inhibitor empagliflozin in activated primary microglia. Cells, 11.","DOI":"10.3390\/cells11193107"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e209805","DOI":"10.1212\/WNL.0000000000209805","article-title":"SGLT2 inhibitor use and risk of dementia and Parkinson disease among patients with type 2 diabetes","volume":"103","author":"Kim","year":"2024","journal-title":"Neurology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/jgs.18306","article-title":"Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies","volume":"71","author":"Tang","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"14791641221098168","DOI":"10.1177\/14791641221098168","article-title":"The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study","volume":"19","author":"Siao","year":"2022","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.amjmed.2024.06.030","article-title":"Association between SGLT2 inhibitors and risk of dementia and Parkinson\u2019s disease: A meta-analysis of 12 randomized controlled trials","volume":"137","author":"Jaiswal","year":"2024","journal-title":"Am. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s43440-023-00469-1","article-title":"Is metformin neuroprotective against diabetes mellitus-induced neurodegeneration? An updated graphical review of molecular basis","volume":"75","author":"Karami","year":"2023","journal-title":"Pharmacol. Rep."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13195-024-01645-y","article-title":"Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: A systematic review and network meta-analysis of observational studies and randomized controlled trials","volume":"16","author":"Li","year":"2024","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11481-024-10140-y","article-title":"Canagliflozin mitigated cognitive impairment in streptozotocin-induced sporadic Alzheimer\u2019s disease in mice: Role of AMPK\/SIRT-1 signaling pathway in modulating neuroinflammation","volume":"19","author":"Khamies","year":"2024","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Lee, C.T., Lin, K.D., Hsieh, C.F., and Wang, J.Y. (2023). SGLT2 inhibitor canagliflozin alleviates high glucose-induced inflammatory toxicity in BV-2 microglia. Biomedicines, 12.","DOI":"10.3390\/biomedicines12010036"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Oelze, M., Kr\u00f6ller-Sch\u00f6n, S., Welschof, P., Jansen, T., Hausding, M., Mikhed, Y., Stamm, P., Mader, M., Zin\u00dfius, E., and Agdauletova, S. (2014). The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112394"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Erdogan, M.A., Yusuf, D., Christy, J., Solmaz, V., Erdogan, A., Taskiran, E., and Erbas, O. (2018). Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy. BMC Neurol., 18.","DOI":"10.1186\/s12883-018-1086-4"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"106062","DOI":"10.1016\/j.phrs.2022.106062","article-title":"Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment","volume":"176","author":"Rizzo","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/neup.12665","article-title":"Sodium\/glucose cotransporter 2 is expressed in choroid plexus epithelial cells and ependymal cells in human and mouse brains","volume":"40","author":"Chiba","year":"2020","journal-title":"Neuropathology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e13653","DOI":"10.1111\/acel.13653","article-title":"Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM-HET3 mice","volume":"21","author":"Jayarathne","year":"2022","journal-title":"Aging Cell"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-024-02255-6","article-title":"SGLT1 and SGLT2 Inhibition, Circulating Metabolites, and Cerebral Small Vessel Disease: A Mediation Mendelian Randomization Study","volume":"23","author":"Lv","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"115456","DOI":"10.1016\/j.biopha.2023.115456","article-title":"The Protein Arginine Methyltransferase Family (PRMTs) Regulates Metastases in Various Tumors: From Experimental Study to Clinical Application","volume":"167","author":"Ning","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41440-023-01522-5","article-title":"Inhibiting SGLTs Diminishes Sympathetic Output by Reducing Rostral Ventrolateral Medulla (RVLM) Neuron Activity","volume":"47","author":"Rahman","year":"2024","journal-title":"Hypertens. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/psp4.12498","article-title":"Differentiating the sodium-glucose cotransporter 1 inhibition capacity of canagliflozin vs. dapagliflozin and empagliflozin using quantitative systems pharmacology modeling","volume":"9","author":"Sokolov","year":"2020","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jjcc.2022.09.001","article-title":"Radial Versus Femoral Access in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: A Propensity-Matched Analysis From Real-World Data of the K-ACTIVE Registry","volume":"81","author":"Mori","year":"2023","journal-title":"J. Cardiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"107260","DOI":"10.1016\/j.isci.2023.107260","article-title":"SGLT1\/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes","volume":"26","author":"Herat","year":"2023","journal-title":"iScience"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s40120-025-00832-9","article-title":"SGLT-2 Inhibitors in the Prevention and Progression of Neurodegenerative Diseases: A Narrative Review","volume":"14","author":"Kostrzewska","year":"2025","journal-title":"Neurol. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"176381","DOI":"10.1016\/j.ejphar.2024.176381","article-title":"Canagliflozin Protects against Hyperglycemia-Induced Cerebrovascular Injury by Preventing Blood-Brain Barrier (BBB) Disruption via AMPK\/Sp1\/Adenosine A2A Receptor","volume":"968","author":"Liu","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Z\u0142otek, M., Kurowska, A., Herbet, M., and Pi\u0105tkowska-Chmiel, I. (2023). GLP-1 analogs, SGLT-2, and DPP-4 inhibitors: A triad of hope for Alzheimer\u2019s disease therapy. Biomedicines, 11.","DOI":"10.3390\/biomedicines11113035"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T., Ta, Q.T.H., Nguyen, T.K.O., Nguyen, T.T.D., and Van Giau, V. (2020). Type 3 diabetes and its role implications in Alzheimer\u2019s disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093165"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Yang, Y., Wu, Y., Zhang, S., and Song, W. (2013). High glucose promotes A\u03b2 production by inhibiting APP degradation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069824"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"10242","DOI":"10.1038\/ncomms10242","article-title":"Elevated glucose and oligomeric \u03b2-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation","volume":"7","author":"Akhtar","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.brainresrev.2007.09.001","article-title":"Common pathological processes in Alzheimer disease and type 2 diabetes: A review","volume":"56","author":"Li","year":"2007","journal-title":"Brain Res. Rev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/13872877251329474","article-title":"Neuroprotective effects of SGLT2 inhibitors empagliflozin and dapagliflozin on A\u03b21-42-induced neurotoxicity and neuroinflammation in cellular models of Alzheimer\u2019s disease","volume":"105","author":"Alami","year":"2025","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1177\/13872877241309674","article-title":"SGLT2 inhibition, circulating biomarkers, and Alzheimer\u2019s disease: A Mendelian randomization study","volume":"103","author":"Yang","year":"2025","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Liao, X., Xu, J., Yin, J., Li, S., Li, M., Shi, X., Zhang, S., Li, C., and Xu, W. (2024). The promising potency of sodium-glucose cotransporter 2 inhibitors in the prevention of and as treatment for cognitive impairment among type 2 diabetes patients. Biomedicines, 12.","DOI":"10.3390\/biomedicines12122783"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e20230187","DOI":"10.1590\/2175-8239-jbn-2023-0187en","article-title":"SGLT2 Inhibitors and NLRP3 Inflammasome: Potential Target in Diabetic Kidney Disease","volume":"46","author":"Lass","year":"2024","journal-title":"J. Bras. Nefrol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Xu, J., Kitada, M., Ogura, Y., Liu, H., and Koya, D. (2021). Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells. Cells, 10.","DOI":"10.3390\/cells10061457"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.116.235069","article-title":"Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation","volume":"359","author":"Benetti","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"115271","DOI":"10.1016\/j.expneurol.2025.115271","article-title":"Neuroprotective roles of SGLT2 and DPP4 inhibitors: Modulating ketone metabolism and suppressing NLRP3 inflammasome in T2D induced Alzheimer\u2019s disease","volume":"390","author":"Sim","year":"2025","journal-title":"Exp. Neurol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e47202","DOI":"10.15252\/embr.201847202","article-title":"Tau accumulation triggers STAT1-dependent memory deficits by suppressing NMDA receptor expression","volume":"20","author":"Li","year":"2019","journal-title":"EMBO Rep."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"9944880","DOI":"10.1155\/2021\/9944880","article-title":"Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-\u03baB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways","volume":"2021","author":"Lee","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"115755","DOI":"10.1016\/j.biopha.2023.115755","article-title":"SGLT2 and DPP4 inhibitors improve Alzheimer\u2019s disease-like pathology and cognitive function through distinct mechanisms in a T2D-AD mouse model","volume":"168","author":"Sim","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1479164118783756","article-title":"Effects of sodium glucose co-transporter 2 inhibitors on the kidney","volume":"15","author":"Neeland","year":"2018","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.RES.0000137170.41939.d9","article-title":"Is the failing heart energy starved? On using chemical energy to support cardiac function","volume":"95","author":"Ingwall","year":"2004","journal-title":"Circ. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.tem.2021.07.006","article-title":"Ketone bodies for the failing heart: Fuels that can fix the engine?","volume":"32","author":"Yurista","year":"2021","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","article-title":"Ketones: The double-edged sword of SGLT2 inhibitors?","volume":"66","author":"Lupsa","year":"2023","journal-title":"Diabetologia"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-nutr-071816-064916","article-title":"\u03b2-Hydroxybutyrate: A signaling metabolite","volume":"37","author":"Newman","year":"2017","journal-title":"Annu. Rev. Nutr."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jnr.20307","article-title":"Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain","volume":"79","author":"Pellerin","year":"2005","journal-title":"J. Neurosci. Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-nutr-111120-111518","article-title":"Metabolic and Signaling Roles of Ketone Bodies in Health and Disease","volume":"41","author":"Puchalska","year":"2021","journal-title":"Annu. Rev. Nutr."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.molcel.2016.03.036","article-title":"Metabolic Regulation of Gene Expression by Histone Lysine \u03b2-Hydroxybutyrylation","volume":"62","author":"Xie","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e15092","DOI":"10.7554\/eLife.15092","article-title":"Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body \u03b2-hydroxybutyrate","volume":"5","author":"Sleiman","year":"2016","journal-title":"eLife"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: Beyond the glucose-lowering effect","volume":"19","author":"Ni","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","article-title":"Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease","volume":"20","author":"Butterfield","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jamaneurol.2025.0353","article-title":"GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias","volume":"82","author":"Tang","year":"2025","journal-title":"JAMA Neurol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"102751","DOI":"10.1016\/j.arr.2025.102751","article-title":"Reducing Alzheimer\u2019s disease risk with SGLT2 inhibitors: From glycemic control to neuroprotection","volume":"108","author":"Alami","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Mui, J.V., Zhou, J., Lee, S., Leung, K.S.K., Lee, T.T.L., Chou, O.H.I., Tsang, S.L., Wai, A.K.C., Liu, T., and Wong, W.T. (2021). Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.747620"},{"key":"ref_172","first-page":"141","article-title":"12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus","volume":"10","author":"Perna","year":"2018","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e70416","DOI":"10.1002\/alz.70416","article-title":"Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer\u2019s disease: A randomized controlled trial","volume":"21","author":"Burns","year":"2025","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamaneurol.2025.0360","article-title":"Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis","volume":"82","author":"Seminer","year":"2025","journal-title":"JAMA Neurol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/10600280251317495","article-title":"Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Nervous System Disorders: A Systematic Review and Meta-Analysis","volume":"59","author":"Xu","year":"2025","journal-title":"Ann. Pharmacother."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Tseng, P.T., Zeng, B.Y., Hsu, C.W., Hung, C.M., Carvalho, A.F., Stubbs, B., Chen, Y.W., Chen, T.Y., Lei, W.T., and Chen, J.J. (2025). The Pharmacodynamics-Based Prophylactic Benefits of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Neurodegenerative Diseases: Evidence from a Network Meta-Analysis. BMC Med., 23.","DOI":"10.1186\/s12916-025-04018-w"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"C240","DOI":"10.1152\/ajpcell.00317.2012","article-title":"Regional distribution of SGLT activity in rat brain in vivo","volume":"304","author":"Yu","year":"2013","journal-title":"Am. J. Physiol. -Cell Physiol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"12629","DOI":"10.3390\/ijms131012629","article-title":"The Role of Glucose Transporters in Brain Disease: Diabetes and Alzheimer\u2019s Disease","volume":"13","author":"Shah","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00424-020-02433-x","article-title":"Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: From molecular discovery to clinical application","volume":"472","author":"Gyimesi","year":"2020","journal-title":"Pflug. Arch. Eur. J. Physiol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/14656566.2024.2362265","article-title":"Empagliflozin increases plasma levels of citrulline, histidine, and \u03b1-aminobutyric acid in patients with type 2 diabetes: Effects of a sodium-glucose co-transporter 2 inhibitor on the plasma amino acid profile","volume":"25","author":"Jojima","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"111248","DOI":"10.1016\/j.nut.2021.111248","article-title":"Citrulline supplementation improves spatial memory in a murine model for Alzheimer\u2019s disease","volume":"90","year":"2021","journal-title":"Nutrition"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1021\/ac301243k","article-title":"Toward a predictive model of Alzheimer\u2019s disease progression using capillary electrophoresis-mass spectrometry metabolomics","volume":"84","author":"Kivipelto","year":"2012","journal-title":"Anal. Chem."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/mnfr.201300033","article-title":"Arginine and nitric oxide synthase: Regulatory mechanisms and cardiovascular aspects","volume":"58","author":"Lorin","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/eurheartj\/eht544","article-title":"Endothelial nitric oxide: Protector of a healthy mind","volume":"35","author":"Katusic","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuro.2018.03.001","article-title":"Amelioration by nitric oxide (NO) mimetics on neurobehavioral and biochemical changes in experimental model of Alzheimer\u2019s disease in rats","volume":"66","author":"Dubey","year":"2018","journal-title":"Neurotoxicology"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e003666","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Tecce, N., de Alteriis, G., de Alteriis, G., Verde, L., Tecce, M.F., Colao, A., and Muscogiuri, G. (2024). Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure among Patients with Type 1 Diabetes. Healthcare, 12.","DOI":"10.20944\/preprints202402.1417.v1"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Mateoc, T., Dumitrascu, A.L., Flangea, C., Puscasiu, D., Vlad, T., Popescu, R., Marina, C., and Vlad, D.C. (2025). SGLT2 Inhibitors: From Structure-Effect Relationship to Pharmacological Response. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146937"},{"key":"ref_189","first-page":"10.1039\/D0NJ02263B","article-title":"Synthesis of (+\/\u2212)-Pregabalin and its novel lipophilic \u03b2-alkyl-substituted analogues from fatty chains","volume":"44","author":"Mass","year":"2020","journal-title":"New J. Chem."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"12536","DOI":"10.1021\/acs.jmedchem.3c01138","article-title":"Design, Synthesis, and Biological Evaluation of Thioglucoside Analogues of Gliflozin as Potent New Gliflozin Drugs","volume":"66","author":"Feng","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ejoc.201601264","article-title":"Convenient Synthesis of 3-Glycosylated Isocoumarins","volume":"2017","author":"Sudarshan","year":"2017","journal-title":"Eur. J. Org. Chem."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.bmcl.2018.12.057","article-title":"Discovery of an isocoumarin analogue that modulates neuronal functions via neurotrophin receptor TrkB","volume":"29","author":"Sudarshan","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s43094-026-00963-2","article-title":"Exploring the Potential of SGLT2 Inhibitors in Alzheimer\u2019s Disease: Network Pharmacology, Molecular Docking, and MD Simulation Study","volume":"12","author":"Miah","year":"2026","journal-title":"Future J. Pharm. Sci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.2147\/IJN.S454553","article-title":"Brain Targeting Nanomedicines: Pitfalls and Promise","volume":"19","author":"Kakinen","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1089\/dia.2018.0081","article-title":"Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care","volume":"20","author":"Danne","year":"2018","journal-title":"Diabetes Technol. Ther."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2147\/DMSO.S258593","article-title":"Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice","volume":"13","author":"Nguyen","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1515\/tnsci-2022-0258","article-title":"Nanotechnology-based drug delivery for the treatment of CNS disorders","volume":"13","author":"Mittal","year":"2022","journal-title":"Transl. Neurosci."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"111898","DOI":"10.1016\/j.mad.2023.111898","article-title":"A Feasibility Study of the Combination of Intranasal Insulin with Oral Semaglutide for Cognition in Older Adults with Metabolic Syndrome at High Dementia Risk\u2014Study Rationale and Design","volume":"218","author":"Davidy","year":"2024","journal-title":"Mech. Ageing Dev."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13024-025-00894-1","article-title":"Effect of Antidiabetic Drugs in Alzheimer\u2019s Disease: A Systematic Review of Preclinical and Clinical Studies","volume":"20","year":"2025","journal-title":"Mol. Neurodegener."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/5051\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:49:45Z","timestamp":1780634985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/5051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":200,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27115051"],"URL":"https:\/\/doi.org\/10.3390\/ijms27115051","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}